ELITE PHARMACEUTICALS INC /NV/ ELTP
ELITE PHARMACEUTICALS INC /NV/ (ELTP) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $148.9M at a 30.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.08 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1961 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.685 |
| Retained earnings / assets | -0.548 |
| EBIT / assets | 0.355 |
| Equity / liabilities | 2.509 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | 6/9 | 7.73 | 9.5 | +77.1% |
| MGNX | MACROGENICS INC | 2/9 | -12.89 | — | -0.3% |
| KPTI | Karyopharm Therapeutics Inc. | 2/9 | — | — | +0.6% |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | 2/9 | — | — | +7.4% |
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | 3/9 | -1.75 | — | +0.5% |
| XNCR | Xencor Inc | 3/9 | 2.23 | — | +13.7% |
About ELITE PHARMACEUTICALS INC /NV/
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
FAQ
Is ELTP financially healthy?
ELITE PHARMACEUTICALS INC /NV/'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ELTP pay a dividend?
No, ELITE PHARMACEUTICALS INC /NV/ does not currently pay a dividend.
How profitable is ELTP?
In FY2026, ELITE PHARMACEUTICALS INC /NV/ had a net margin of 30.1% and a return on equity of 45.4%.
What is ELTP's P/E ratio?
ELITE PHARMACEUTICALS INC /NV/'s trailing price-to-earnings (P/E) ratio is about 9.5×, based on its latest annual earnings.
Is ELTP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ELITE PHARMACEUTICALS INC /NV/: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 9.5×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.